|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: BPHL |
Gene summary for BPHL |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | BPHL | Gene ID | 670 |
| Gene name | biphenyl hydrolase like | |
| Gene Alias | BPH-RP | |
| Cytomap | 6p25.2 | |
| Gene Type | protein-coding | GO ID | GO:0006082 | UniProtAcc | A0A024QZY0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 670 | BPHL | LZE7T | Human | Esophagus | ESCC | 1.36e-08 | 5.29e-01 | 0.0667 |
| 670 | BPHL | LZE20T | Human | Esophagus | ESCC | 7.23e-03 | 1.02e-01 | 0.0662 |
| 670 | BPHL | LZE22T | Human | Esophagus | ESCC | 4.43e-04 | 3.78e-01 | 0.068 |
| 670 | BPHL | LZE24T | Human | Esophagus | ESCC | 4.87e-11 | 3.35e-01 | 0.0596 |
| 670 | BPHL | LZE6T | Human | Esophagus | ESCC | 8.85e-03 | 1.41e-01 | 0.0845 |
| 670 | BPHL | P1T-E | Human | Esophagus | ESCC | 1.38e-06 | 2.68e-01 | 0.0875 |
| 670 | BPHL | P2T-E | Human | Esophagus | ESCC | 1.21e-38 | 6.73e-01 | 0.1177 |
| 670 | BPHL | P4T-E | Human | Esophagus | ESCC | 1.57e-30 | 6.29e-01 | 0.1323 |
| 670 | BPHL | P5T-E | Human | Esophagus | ESCC | 2.37e-08 | 6.08e-02 | 0.1327 |
| 670 | BPHL | P8T-E | Human | Esophagus | ESCC | 1.35e-14 | 2.31e-01 | 0.0889 |
| 670 | BPHL | P9T-E | Human | Esophagus | ESCC | 8.54e-04 | 1.13e-01 | 0.1131 |
| 670 | BPHL | P10T-E | Human | Esophagus | ESCC | 4.88e-06 | 1.15e-01 | 0.116 |
| 670 | BPHL | P11T-E | Human | Esophagus | ESCC | 2.82e-12 | 5.22e-01 | 0.1426 |
| 670 | BPHL | P12T-E | Human | Esophagus | ESCC | 1.40e-22 | 4.70e-01 | 0.1122 |
| 670 | BPHL | P15T-E | Human | Esophagus | ESCC | 2.67e-19 | 4.23e-01 | 0.1149 |
| 670 | BPHL | P16T-E | Human | Esophagus | ESCC | 2.28e-26 | 3.92e-01 | 0.1153 |
| 670 | BPHL | P17T-E | Human | Esophagus | ESCC | 1.15e-04 | 2.37e-01 | 0.1278 |
| 670 | BPHL | P19T-E | Human | Esophagus | ESCC | 3.74e-05 | 5.35e-01 | 0.1662 |
| 670 | BPHL | P20T-E | Human | Esophagus | ESCC | 1.66e-08 | 1.76e-01 | 0.1124 |
| 670 | BPHL | P21T-E | Human | Esophagus | ESCC | 6.03e-31 | 5.25e-01 | 0.1617 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000941020 | Esophagus | ESCC | response to xenobiotic stimulus | 253/8552 | 462/18723 | 4.55e-05 | 3.58e-04 | 253 |
| GO:000963620 | Esophagus | ESCC | response to toxic substance | 150/8552 | 262/18723 | 1.00e-04 | 7.12e-04 | 150 |
| GO:00065203 | Liver | NAFLD | cellular amino acid metabolic process | 63/1882 | 284/18723 | 1.14e-09 | 2.17e-07 | 63 |
| GO:00094107 | Liver | NAFLD | response to xenobiotic stimulus | 88/1882 | 462/18723 | 2.53e-09 | 4.11e-07 | 88 |
| GO:00714663 | Liver | NAFLD | cellular response to xenobiotic stimulus | 33/1882 | 177/18723 | 3.54e-04 | 5.36e-03 | 33 |
| GO:00068054 | Liver | NAFLD | xenobiotic metabolic process | 22/1882 | 111/18723 | 1.42e-03 | 1.58e-02 | 22 |
| GO:00096367 | Liver | NAFLD | response to toxic substance | 41/1882 | 262/18723 | 2.83e-03 | 2.57e-02 | 41 |
| GO:000963612 | Liver | Cirrhotic | response to toxic substance | 104/4634 | 262/18723 | 5.63e-08 | 1.74e-06 | 104 |
| GO:000941012 | Liver | Cirrhotic | response to xenobiotic stimulus | 165/4634 | 462/18723 | 6.82e-08 | 2.09e-06 | 165 |
| GO:000652011 | Liver | Cirrhotic | cellular amino acid metabolic process | 103/4634 | 284/18723 | 8.88e-06 | 1.30e-04 | 103 |
| GO:00714661 | Liver | Cirrhotic | cellular response to xenobiotic stimulus | 66/4634 | 177/18723 | 1.34e-04 | 1.31e-03 | 66 |
| GO:000680511 | Liver | Cirrhotic | xenobiotic metabolic process | 43/4634 | 111/18723 | 7.51e-04 | 5.54e-03 | 43 |
| GO:00065202 | Liver | HCC | cellular amino acid metabolic process | 167/7958 | 284/18723 | 1.91e-08 | 4.56e-07 | 167 |
| GO:000963622 | Liver | HCC | response to toxic substance | 153/7958 | 262/18723 | 1.37e-07 | 2.58e-06 | 153 |
| GO:000941022 | Liver | HCC | response to xenobiotic stimulus | 248/7958 | 462/18723 | 6.47e-07 | 1.02e-05 | 248 |
| GO:00714662 | Liver | HCC | cellular response to xenobiotic stimulus | 93/7958 | 177/18723 | 4.35e-03 | 1.89e-02 | 93 |
| GO:000170116 | Oral cavity | OSCC | in utero embryonic development | 207/7305 | 367/18723 | 7.92e-12 | 2.95e-10 | 207 |
| GO:000963618 | Oral cavity | OSCC | response to toxic substance | 137/7305 | 262/18723 | 7.94e-06 | 8.52e-05 | 137 |
| GO:000941018 | Oral cavity | OSCC | response to xenobiotic stimulus | 222/7305 | 462/18723 | 4.00e-05 | 3.48e-04 | 222 |
| GO:000963619 | Oral cavity | LP | response to toxic substance | 86/4623 | 262/18723 | 1.74e-03 | 1.32e-02 | 86 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| BPHL | SNV | Missense_Mutation | rs774197466 | c.511G>A | p.Glu171Lys | p.E171K | Q86WA6 | protein_coding | tolerated(0.11) | benign(0.042) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| BPHL | insertion | Frame_Shift_Ins | novel | c.361_362insAACCTCCGCCTCCCGGGTTCAAGCAATTCTCCTGCCTCAGCCTC | p.Ala121GlufsTer19 | p.A121Efs*19 | Q86WA6 | protein_coding | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD | ||
| BPHL | insertion | In_Frame_Ins | novel | c.821_822insACTTAG | p.Leu274_His275insLeuArg | p.L274_H275insLR | Q86WA6 | protein_coding | TCGA-B6-A0IN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | ||
| BPHL | insertion | Nonsense_Mutation | novel | c.823_824insTTTCATCCTAGAAGCTTTACCACTTTTACTGTTTCT | p.His275delinsLeuSerSerTerLysLeuTyrHisPheTyrCysPheTyr | p.H275delinsLSS*KLYHFYCFY | Q86WA6 | protein_coding | TCGA-B6-A0IN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | ||
| BPHL | insertion | Nonsense_Mutation | novel | c.396_397insCCTCCTGAGTAGCTGGGATTACAGGCACATGCCACTAT | p.Val133ProfsTer4 | p.V133Pfs*4 | Q86WA6 | protein_coding | TCGA-BH-A0B4-01 | Breast | breast invasive carcinoma | Male | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD | ||
| BPHL | SNV | Missense_Mutation | rs151267393 | c.830N>A | p.Arg277His | p.R277H | Q86WA6 | protein_coding | deleterious(0.01) | probably_damaging(0.986) | TCGA-IR-A3LB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| BPHL | SNV | Missense_Mutation | novel | c.414N>C | p.Trp138Cys | p.W138C | Q86WA6 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-VS-A8EI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| BPHL | SNV | Missense_Mutation | c.793N>T | p.His265Tyr | p.H265Y | Q86WA6 | protein_coding | tolerated(0.28) | benign(0.031) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| BPHL | SNV | Missense_Mutation | rs192366834 | c.184G>A | p.Ala62Thr | p.A62T | Q86WA6 | protein_coding | tolerated(0.16) | benign(0.034) | TCGA-DM-A1HB-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
| BPHL | SNV | Missense_Mutation | c.131N>C | p.Val44Ala | p.V44A | Q86WA6 | protein_coding | tolerated(0.1) | benign(0.017) | TCGA-F4-6570-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |